Recombinant Human TNFRSF10A (TRAIL R1)-Fc Chimera (carrier-free)

Pricing & Availability
Regulatory Status
Other Names
Tumor necrosis factor receptor superfamily member 10A (TNFRSF10A), TNF-related apoptosis-inducing ligand receptor 1 (TRAIL R1), TRAIL receptor 1, Death receptor 4 (DR4), CD261, APO2
Ave. Rating
Submit a Review
Product Citations
Human TNFRSF10A inhibits the cytotoxic effect induced by recombinant human TRAIL on mouse L929 cells.
  • Human_TNFRSF10A_TRAIL-R1_RECOM_1_121217
    Human TNFRSF10A inhibits the cytotoxic effect induced by recombinant human TRAIL on mouse L929 cells.
  • Human_TNFRSF10A_TRAIL-R1_RECOM_2_121217
    Human TNFRSF10A was aliquoted in PBS, pH 7 at 0.1 mg/ml and one aliquot was kept at 4°C (control), and another was freeze/thawed four times (4x freeze/thaws). After this procedure, the samples were tested for their ability to inhibit the cytotoxic effect induced by recombinant human TRAIL on mouse L929 cells.
Cat # Size Price Quantity Check Availability Save
768304 25 µg 118€
Check Availability

Need larger quantities of this item?
Request Bulk Quote
768306 100 µg 272€
Check Availability

Need larger quantities of this item?
Request Bulk Quote

TNFRSF10A, also called TRAIL R1 and DR4, is a member of the TNF receptor superfamily. It contains a cysteine-rich extracellular domain, a transmembrane domain and an intracellular death domain, which mediates interactions between death receptor and death domain-containing adaptor proteins. When the trimeric ligand TRAIL (TNFSF10) is bound, homotrimer TNFRSF10A interacts with the adaptor protein Fas-associated death domain (FADD), in turn recruits caspase-8 and assembles a death-inducing signaling complex (DISC) that initiates apoptosis. There are decoy receptors, TRAIL R3 (DcR1), TRAIL R4 (DcR2) and OPG, which antagonize the apoptotic effect via competitive ligand binding. Human TNFRSF10A shows 52% identity to human TNFRSF10B and there is some functional redundancy. Several evidences indicated that TNFRSF10A play roles in tumorigenesis and DNA damage response. Some studies indicated the role of TNFRSF10A in cancer predisposition. A rare allele of TNFRSF10A was found to be more frequent in chronic lymphocytic leukemia (CLL), mantle cell lymphoma (MCL), prostate cancer, bladder cancer, colorectal cancer and head and neck squamous cell carcinoma (HNSCC). Agonistic monoclonal antibodies against TNFRSF10A, which can induce apoptosis in the absence of TRAIL, are used for cancer therapies. However, some studies have suggested that TNFRSF10B contributes more than TNFRSF10A to TRAIL-induced apoptosis in cancer cells that express both receptors. The expression of TNFRSF10A is inducible and up-regulated by DNA damage in p53-dependent manner.

Product Details
Technical Data Sheet (pdf)

Product Details

Human TNFRSF10A, amino acid (Met1-Asn239) (Accession: # AAC51226), with a linker (GS) and a C-terminal human IgG (Pro100-Lys330), was expressed in 293E cells.
>95%, as determined by Coomassie stained SDS-PAGE.
0.22 µm filtered protein solution is in 1x PBS.
Endotoxin Level
Less than 0.1 EU/µg cytokine as determined by the LAL method.
10 and 25 µg sizes are bottled at 200 µg/mL. 100 µg size and larger sizes are lot-specific and bottled at the concentration indicated on the vial. To obtain lot-specific concentration and expiration, please enter the lot number in our Certificate of Analysis online tool.
Storage & Handling
Unopened vial can be stored between 2°C and 8°C for up to 2 weeks, at -20°C for up to six months, or at -70°C or colder until the expiration date. For maximum results, quick spin vial prior to opening. The protein can be aliquoted and stored at -20°C or colder. Stock solutions can also be prepared at 50 - 100 µg/mL in appropriate sterile buffer, carrier protein such as 0.2 - 1% BSA or HSA can be added when preparing the stock solution. Aliquots can be stored between 2°C and 8°C for up to one week and stored at -20°C or colder for up to 3 months. Avoid repeated freeze/thaw cycles.
The ED50 is 0.18-0.9 ng/mL, as determined by inhibition of human TRAIL-mediated cytotoxicity on L929 cells in the presence of 12 ng/mL cross-linked recombinant human TRAIL (Cat. No. 752902) and 1.0 µg/ml Actinomycin D.


Application Notes

BioLegend carrier-free recombinant proteins provided in liquid format are shipped on blue-ice. Our comparison testing data indicates that when handled and stored as recommended, the liquid format has equal or better stability and shelf-life compared to commercially available lyophilized proteins after reconstitution. Our liquid proteins are verified in-house to maintain activity after shipping on blue ice and are backed by our 100% satisfaction guarantee. If you have any concerns, contact us at

Antigen Details

Homodimer, disulfide bond-linked

Membrane; liver, lung, kidney, testis, prostate, ovary, placenta intestine, Thymus, spleen, heart; peripheral blood leukocytes

TNFRSF10A play roles in tumorigenesis, immune response and DNA damage response. TNFRSF10A induces apoptosis upon the binding of ligand, TNFSF10.
Biology Area
Apoptosis/Tumor Suppressors/Cell Death, Cell Biology, Immunology
Molecular Family
CD Molecules, Cytokine/Chemokine Receptors, Soluble Receptors
Antigen References

1. Ashkenazi A. 2002. Nat Rev Cancer 2: 420.
2. LeBlanc HN et al. 2003. Cell Death Differ 10: 66.
3. Chuntharapai A et al. 2001. J Immunol 166: 4891.
4. Pukac L et al. 2005. Br J Cancer 92: 1430.
5. Kelley RF et al. 2005. J Biol Chem 280: 2205.
6. Wolf S et al. 2006. Int J Cancer 118: 1831.
7. Frank B et al. 2006. Cancer Epidemiol Biomarkers Prev 15: 2002.
8. Walczak H et al. 1997. EMBO J 16: 5386.
9. Johnstone RW et al. 2008. Nat Rev Cancer 8: 782.
10. Guan B et al. 2001. J Cell Physiol 188: 98. 

Gene ID
8797 View all products for this Gene ID
View information about TNFRSF10A on

Related FAQs

Why choose BioLegend recombinant proteins?

     • Each lot of product is quality-tested for bioactivity as indicated on the data sheet.
     • Greater than 95% Purity or higher, tested on every lot of product.
     • 100% Satisfaction Guarantee for quality performance, stability, and consistency.
     • Ready-to-use liquid format saves time and reduces challenges associated with reconstitution.
     • Bulk and customization available. Contact us.
     • Learn more about our Recombinant Proteins.

How does the activity of your recombinant proteins compare to competitors?

We quality control each and every lot of recombinant protein. Not only do we check its bioactivity, but we also compare it against other commercially available recombinant proteins. We make sure each recombinant protein’s activity is at least as good as or better than the competition’s. In order to provide you with the best possible product, we ensure that our testing process is rigorous and thorough. If you’re curious and eager to make the switch to BioLegend recombinants, contact your sales representative today!

What is the specific activity or ED50 of my recombinant protein?

The specific activity range of the protein is indicated on the product datasheets. Because the exact activity values on a per unit basis can largely fluctuate depending on a number of factors, including the nature of the assay, cell density, age of cells/passage number, culture media used, and end user technique, the specific activity is best defined as a range and we guarantee the specific activity of all our lots will be within the range indicated on the datasheet. Please note this only applies to recombinants labeled for use in bioassays. ELISA standard recombinant proteins are not recommended for bioassay usage as they are not tested for these applications.

Have your recombinants been tested for stability?

Our testing shows that the recombinant proteins are able to withstand room temperature for a week without losing activity. In addition the recombinant proteins were also found to withstand four cycles of freeze and thaw without losing activity.

Does specific activity of a recombinant protein vary between lots?

Specific activity will vary for each lot and for the type of experiment that is done to validate it, but all passed lots will have activity within the established ED50 range for the product and we guarantee that our products will have lot-to-lot consistency. Please conduct an experiment-specific validation to find the optimal ED50 for your system.

How do you convert activity as an ED50 in ng/ml to a specific activity in Units/mg?

Use formula Specific activity (Units/mg) = 10^6/ ED50 (ng/mL)

Go To Top Version: 0    Revision Date: 12.13.2017

For Research Use Only. Not for diagnostic or therapeutic use.


This product is supplied subject to the terms and conditions, including the limited license, located at ("Terms") and may be used only as provided in the Terms. Without limiting the foregoing, BioLegend products may not be used for any Commercial Purpose as defined in the Terms, resold in any form, used in manufacturing, or reverse engineered, sequenced, or otherwise studied or used to learn its design or composition without express written approval of BioLegend. Regardless of the information given in this document, user is solely responsible for determining any license requirements necessary for user’s intended use and assumes all risk and liability arising from use of the product. BioLegend is not responsible for patent infringement or any other risks or liabilities whatsoever resulting from the use of its products.


BioLegend, the BioLegend logo, and all other trademarks are property of BioLegend, Inc. or their respective owners, and all rights are reserved.


8999 BioLegend Way, San Diego, CA 92121
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587


Login / Register
Remember me
Forgot your password? Reset password?
Create an Account